Wikipedia

Management of HIV/AIDS

This is an old revision of this page, as edited by KBlott (talk | contribs) at 16:52, 18 October 2010 (→Adverse effects). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

"HAART" redirects here. For UK estate agency Haart, see Spicerhaart.

Antiretroviral drugs are medications for the treatment of infection by retroviruses, primarily HIV. When several such drugs, typically three or four, are taken in combination, the approach is known as Highly Active Antiretroviral Therapy, or HAART. The American National Institutes of Health and other organizations recommend offering antiretroviral treatment to all patients with AIDS. Because of the complexity of selecting and following a regimen, the severity of the side-effects and the importance of compliance to prevent viral resistance, however, such organizations emphasize the importance of involving patients in therapy choices, and recommend analyzing the risks and the potential benefits to patients with low viral loads.[1]

There are different classes of antiretroviral drugs that act at different stages of the HIV life-cycle.

Classes of drugs

Antiretroviral (ARV) drugs are broadly classified by the phase of the retrovirus life-cycle that the drug inhibits.

Quackery/Alternative Therapy

Naturally occurring antiretrovirals

A variety of natural compounds have been proposed as treatments for HIV-infection. Among these compounds are the spice cumin,[4] the fat AL 721,[5] Chinese cucumber,[6] the herb St John’s wart, the minerals selenium and zinc, beta-carotene (found in carrots), vitamin E,[7] and mushrooms.[8][9][10][11][12][13][14] No natural compounds have ever been shown to inhibit HIV replication in human test subjects.

Synergistic enhancers

Synergistic enhancers either do not possess antiretroviral properties alone [citation needed] or are inadequate or impractical for monotherapy, but when they are taken concurrently with antiretroviral drugs they enhance the effect of one or more of those drugs (often by altering the metabolism of antiretrovirals). These include ritonavir, which is an antiretroviral drug that belongs to the class of protease inhibitors. It can, however, be administered at a "baby" dosage to reduce the liver metabolism of other antiretroviral drugs. This principle was first exploited in the drug Kaletra (Abbott), which is a combination of ritonavir with the protease inhibitor lopinavir at a ratio (v/v) of 1:4. Ritonavir is also used as an enhancer of other protease inhibitors such as saquinavir and atazanavir, and of the investigational integrase inhibitor, GS-9137. Other synergistic enhancers are being investigated for this purpose. [citation needed]

AntiViral HyperActivation Limiting Therapeutics

AV-HALTs (AntiViral HyperActivation Limiting Therapeutics or 'virostatics') combine immunomodulating and antiviral properties to inhibit a specific antiviral target while also limiting the hyper-elevated state of immune system activation driving disease progression.[15]

Combination therapy

The life cycle of HIV can be as short as about 1.5 days from viral entry into a cell, through replication, assembly, and release of additional viruses, to infection of other cells.[16] HIV lacks proofreading enzymes to correct errors made when it converts its RNA into DNA via reverse transcription. Its short life-cycle and high error rate cause the virus to mutate very rapidly, resulting in a high genetic variability of HIV. Most of the mutations either are inferior to the parent virus (often lacking the ability to reproduce at all) or convey no advantage, but some of them have a natural selection superiority to their parent and can enable them to slip past defenses such as the human immune system and antiretroviral drugs. The more active copies of the virus the greater the possibility that one resistant to antiretroviral drugs will be made.

When antiretroviral drugs are used improperly, these multi-drug resistant strains can become the dominant genotypes very rapidly. Improper serial use of the reverse transcriptase inhibitors zidovudine, didanosine, zalcitabine, stavudine, and lamivudine can lead to the development of multi-drug resistant mutations. The mutations can include the V75I, F77L, K103N, F116Y, Q151M, and the M184V mutation. These mutations were observed before protease inhibitors had come into widespread use. The mutants retained sensitivity to the early protease inhibitor saquinavir. These mutants were also sensitive to the rarely used reverse transcriptase inhibitor foscarnet. [17].

Antiretroviral combination therapy defends against resistance by suppressing HIV replication as much as possible.

Combinations of antiretrovirals create multiple obstacles to HIV replication to keep the number of offspring low and reduce the possibility of a superior mutation. If a mutation that conveys resistance to one of the drugs being taken arises, the other drugs continue to suppress reproduction of that mutation. With rare exceptions, no individual antiretroviral drug has been demonstrated to suppress an HIV infection for long; these agents must be taken in combinations in order to have a lasting effect. As a result, the standard of care is to use combinations of antiretroviral drugs. Combinations usually comprise two nucleoside-analogue RTIs and one non-nucleoside-analogue RTI or protease inhibitor.[18] This three drug combination is commonly known as a triple cocktail.[19]

[20] Combinations of antiretrovirals are subject to positive and negative [citation needed] synergies, which limits the number of useful combinations.

In recent years, drug companies have worked together to combine these complex regimens into simpler formulas, termed fixed-dose combinations. For instance, two pills containing two or three medications each can be taken twice daily. [citation needed] This greatly increases the ease with which they can be taken, which in turn increases adherence, and thus their effectiveness over the long-term. Lack of adherence is a cause of resistance development in medication-experienced patients. Patients who maintain proper therapy can stay on one regimen without developing resistance. This greatly increases life expectancy and leaves more drugs available to the individual should the need arise.

Fixed-dose combinations

Fixed dose combinations are multiple antiretroviral drugs combined into a single pill.

Brand Name Drug Names (INN) Date of FDA Approval Company
Combivir zidovudine + lamivudine September 26, 1997 GlaxoSmithKline
Trizivir abacavir + zidovudine + lamivudine November 15, 2000 GlaxoSmithKline
Kaletra lopinavir + ritonavir September 15, 2000 Abbott Laboratories
Epzicom (in USA)
Kivexa (in Europe)		 abacavir + lamivudine August 2, 2004 GlaxoSmithKline
Truvada emtricitabine + tenofovir August 2, 2004 Gilead Sciences
Atripla efavirenz + emtricitabine + tenofovir July 12, 2006 Gilead Sciences and
Bristol-Myers Squibb

Treatment guidelines

Initiation of antiretroviral therapy

Antiretroviral drug treatment guidelines have changed over time. Prior to 1987, no antiretroviral drugs were available and treatment consisted of treating complications from the immunodeficiency. After antiretroviral medications were introduced, most clinicians agreed that HIV positive patients with low CD4 counts should be treated, but no consensus formed as to whether to treat patients with hight CD4 counts.[21] As the demand for new and better drugs mounted, the process by which antiretroviral drugs move from the laboratory to the pharmacy came under intense and extraordinary scrutiny. Academic research institutions and government agencies—the traditional centers of scientific and regulatory power—became targets of political protest. The protests included slogans, pickets, marches and sit ins. Individuals demanded access to antiretrovirals that denialists labelled "experimental". In some trials subjects analyzed their medications to see whether they were active or placebos. Then study subjects shared the active agents with other individuals and took additional, unapproved medications. This violated the terms of the protocol and compromised the validity of the data. Furthermore, the under-representation of some groups affected by HIV in trials was increasingly seen as discrimination against them rather than protection from risk or exploitation.[22]

In 1995, after seven years of these protests, and steadily rising morality rates, some researchers, such as David Ho, added his voice to those [23] already demanding a "hit hard, hit early" approach with aggressive treatment with multiple antiretrovirals early in the course of the infection.[24] A small but vocal group of physicians, none whom are virologists, claim that the Concord study provides evidence that early intervention does not improve survival.[25] There is no scientific validity to this denialist claim.

In contradiction to the denialists who opposed early intervention, recent research has confirmed that mortality rates are almost twice as high when therapy is deferred (until the CD4 count falls below 500) compared to starting therapy when the CD4 count is above 500.[26] The design flaws in the studies that concluded that treatment should be deferred were apparent at the time the studies were published. Experts now acknowledge that there is no scientifically sound empirical evidence for withholding treatment at any stage of HIV infection.[27] There is a consensus among experts that, once initiated, antiretroviral therapy should never be stopped. This is because the selection pressure of incomplete suppression of viral replication in the presence of drug therapy causes the more drug sensitive strains to be selectively inhibited. This allows the drug resistant strains to become dominant. This in turn makes it harder to treat the infected individual as well as anyone else they infect. Antiretroviral therapy is now, finally, offered to anyone who is ready to make this lifelong commitment. Experts remain divided on how to treat people who are not ready to make this commitment.[28]

Current guidelines

The current guidelines use new criteria to consider starting HAART, as described below. However, there remain a range of views on this subject and the decision of whether to commence treatment ultimately rests with the patient and their doctor.

The current guidelines for antiretroviral therapy (ART) from the World Health Organization reflect the 2003 changes to the guidelines and recommend that in resource-limited settings (that is, developing nations), HIV-infected adults and adolescents should start ART when HIV infection has been confirmed and one of the following conditions is present [29]:

  • Clinically advanced HIV disease;
  • WHO Stage IV HIV disease, irrespective of the CD4 cell count;
  • WHO Stage III disease with consideration of using CD4 cell counts less than 350/µl to assist decision making;
  • WHO Stage I or II HIV disease with CD4 cell counts less than 200/µl.

The treatment guidelines specifically for the USA are set by the United States Department of Health and Human Services (DHHS). The current guidelines for adults and adolescents were stated on December 1, 2009.[28]

• Antiretroviral therapy should be initiated in all patients with a history of an AIDS-defining illness or with a CD4 count <350 cells/mm3 (AI).

• Antiretroviral therapy should also be initiated, regardless of CD4 count, in patients with the following conditions: pregnancy (AI), HIV- associated nephropathy (AII), and hepatitis B virus (HBV) coinfection when treatment of HBV is indicated (AIII).

• Antiretroviral therapy is recommended for patients with CD4 counts between 350 and 500 cells/mm3. The Panel was divided on the strength of this recommendation: 55% voted for strong recommendation (A) and 45% voted for moderate recommendation (B) (A/B-II).

• For patients with CD4 counts >500 cells/mm3, the Panel was evenly divided: 50% favor starting antiretroviral therapy at this stage of HIV disease (B); 50% view initiating therapy at this stage as optional (C) (B/C-III).

• Patients initiating antiretroviral therapy should be willing and able to commit to lifelong treatment and should understand the benefits and risks of therapy and the importance of adherence (AIII). Patients may choose to postpone therapy, and providers, on a case-by-case basis, may elect to defer therapy based on clinical and/or psychosocial factors.

Rating of Recommendations: A = Strong; B = Moderate; C = Optional Rating of Evidence: I = data from randomized controlled trials; II = data from well-designed nonrandomized trials or observational cohort studies with long-term clinical outcomes; III = expert opinion

Baseline resistance

In countries with a high rate of baseline resistance, resistance testing is recommended prior to starting treatment; or, if the initiation of treatment is urgent, then a "best guess" treatment regimen should be started, which is then modified on the basis of resistance testing. In the UK, there is 11.8% medium to high-level resistance at baseline to the combination of efavirenz + zidovudine + lamivudine, and 6.4% medium to high level resistance to stavudine + lamivudine + nevirapine.[30]

Regimens

Most current HAART regimens consist of three(3) drugs: 2 NRTIs + a PI/NNRTI/II. Initial regimens use "first-line" drugs with a high efficacy and low side-effect profile.

Treatment guidelines for HIV-1 infected adults in the developed world (that is, those countries with access to all or most therapies and laboratory tests) have been provided by the International AIDS Society-USA(IAS-USA) since 1996. The IAS-USA is a 501(c)(3) not-for-profit organization in the USA (and is not related to the worldwide International AIDS Society or IAS). The IAS-USA guidelines for antiretroviral therapy are developed by a volunteer panel of experts. Its last update was published in August 2008 in the Journal of the American Medical Association.[31] In the 2008 update, the panel recommended that therapy be initiated before the CD4+ cell count declines to below 350/uL and be individualized for the particular patient's situation and comorbidities. For initial therapy, it recommends 2 NRTIs with either an NNRTI, a ritonavir-boosted PI or an integrase inhibitor. In antiretroviral therapy failure, the goal of subsequent treatment is suppression of HIV-1 RNA to below detection; the treatment should ideally have 3 new drugs to which the patient's virus is susceptible. Therapy in selected clinical situations is also described. The IAS-USA also sponsors the development of guidelines for the use of drug resistance testing in patients with HIV-1 infection [32]

Another set of guidelines (distinct from those of the IAS-USA) are provided by an expert panel convened by the U.S. Department of Health and Human Services. The preferred initial regimens in the United States, as of 2009, are[33]:

Children

Because HIV disease progression in children is more rapid than in adults, and laboratory parameters are less predictive of risk for disease progression, in particular for young infants, treatment recommendations from the DHHS have been more aggressive in children than in adults; the current guidelines were published November 3, 2005.[34]

HIV Postexposure Prophylaxis (PEP)

In 2005, the Centers for Disease Control and Prevention in the United States recommended a 28-day HIV drug regimen for those that have been exposed to HIV (HIV Postexposure Prophylaxis [PEP]).[35] The WHO recommendations on treatment are that the minimum that should be used is dual NRTIs for 28 days, with triple therapy (dual NRTIs plus a boosted PI) being offered where there is a risk of resistance.[36] The effectiveness of this intervention has never been precisely ascertained, [citation needed] but postexposure prophylaxis is most effective when administered sooner, though not believed to be effective if given 72 hours after exposure.[36]

Prevention of mother-to-child-transmission (PMTCT)

The use of antiretrovirals is also recommended for the prevention of mother-to-child transmission of HIV-1. The current WHO recommended regimen is as follows: where the pregnant woman does not yet need to start ART for therapeutic reasons, she should start Zidovudine (AZT) from 28 weeks or as soon as possible thereafter, be provided with single-dose Nevirapine (NVP) when entering labour, and be given AZT+3TC for one week following delivery. Meanwhile, whether the mother was on the above or standard ART, the child should be given single dose Nevirapine immediately after delivery and daily Zidovudine until one week old.[37] Complementary measures that may also be used include caesarian section and formula feeding; in some settings, the combination of providing all these measures has succeeded in reducing the risk of infection from 25% to about 1%.[38]

Concerns

There are several concerns about antiretroviral regimens:

  • intolerance: The drugs can have serious side-effects.[39]
  • resistance: If patients miss doses, drug resistance can develop,[1] particularly in individuals with advanced disease.[23]
  • cost: Providing anti-retroviral treatment is costly and resource-intensive, and the majority of the world's infected individuals cannot access treatment services.
  • public health: Individuals who fail to use antiretrovirals properly can develop multi-drug resistant strains which can be passed onto others.[40]

Responses to treatment in older adults

As people age, their bodies are not able to repair and rebuild damaged cells, organs or tissues as rapidly as those of younger people. Diseases like HIV that attack and destroy the body's defenses can exacerbate this slowing and increase the risk of developing additional medical problems like diabetes and high blood pressure, and more physical limitations than younger adults with HIV. In the early years of the HIV epidemic (before HAART), older adults' health deteriorated more rapidly than that of younger individuals - regardless of CD4 count. Several studies found that older adults had lower CD4 counts at diagnosis, faster progression to an AIDS diagnosis, more opportunistic infections, and a shorter survival rate than younger adults, regardless of when they were first diagnosed with HIV.

Recent studies have found that a person's age does not interfere with the ability of HAART to reduce viral load, but there may be differences between younger and older people in how well the immune system responds to treatment. A study published in AIDS (2000) by Roberto Manfredi and Francesco Chiodo examined the effect of HAART on older people (defined as 55 or older) compared to younger people (35 or younger). The study included 21 older people (8 women, 13 men) and 84 younger people (29 women, 55 men). The researchers found that both groups responded to HAART, especially in reducing viral load. However, CD4 counts did not increase as much in the older people relative to the younger ones. On average, CD4 counts increased from 212 to 289 for older adults after one year of HAART. During the same period, CD4 counts rose from 231 to 345 for younger people.

Some people may have a very low CD4 count even though they have an undetectable viral load. [citation needed] This may be related to decreased activity in the thymus (the gland where CD4 cells are made). A 2001 study in AIDS conducted by researchers in Los Angeles included 80 HIV-positive veterans (13 were over 55 and 67 were younger). Although both groups of veterans showed dramatic reductions in viral load once they were on treatment, the researchers found significant differences in CD4 levels at 3, 9, 15, and 18 months. After one year on HAART, average CD4 counts increased by 50 for the older men, compared to increases of 100 for the younger ones. This difference was not related to baseline HIV viral load, coinfection with hepatitis C, or the race/ethnicity of participants. These studies represent an important first step in understanding how their age may affect older adults' response to HIV treatment, but more studies are needed to understand the long-term effects of age on HAART in older adults.

Structured treatment interruptions

If an HIV infection becomes resistant to standard HAART, there are limited options. One option is to take larger combinations of antiretroviral drugs, an approach known as mega-HAART or salvage therapy. Salvage therapy often increases the drugs' side-effects [citation needed].

If an HIV infection becomes sufficiently resistant to antiretroviral-drugs, treatment becomes more complicated and prognosis may deteriorate. Treatment options continue to improve as additional new drugs enter clinical trials. However, the limited distribution of many such drugs denies their benefits to patients, particularly in the developing world.

Drug holidays (or "structured treatment interruptions"), are intentional discontinuations of antiretroviral drug treatment. With the exception of post exposure prophylaxis, current treatment guidelines do not call for the interruption of drug therapy once it has been initiated.

Intermittent therapy was an experimental approach designed to reduce exposure to antiretroviral drugs in an effort to mitigate side-effects. Intermittent therapy differed from treatment interruptions in that it involved using a much shorter cycle of switching on and off the antiviral drugs. Studies of such approaches include schedules of week-on, week-off (also known as "wowo") and five-days-on, two-days-off (also known as "foto"), which skiped treatment on weekends. Intermittent therapy is ineffective and results in drug resistance.

Suppressing HIV is inadequate to restore normal immune function. HIV can damage the ability of the thymus to produce normally diverse T-cells. [citation needed] Also, rapid suppression of HIV and partial restoration of the immune system sometimes produces a dangerous hypersensitivity reaction, immune reconstitution inflammatory syndrome. [citation needed] Research continues in these areas.

Adverse effects

Adverse effects of antiretroviral drugs vary by drug, by ethnicity, by individual, and by interaction with other drugs, including alcohol. Hypersensitivity to some drugs may also occur in some individuals. The following list is not complete, but includes several of the adverse effects experienced by patients taking some antiretroviral drugs:[41]

See also

References

  1. ^ a b Dybul M, Fauci AS, Bartlett JG, Kaplan JE, Pau AK; Panel on Clinical Practices for Treatment of HIV (2002). "Guidelines for using antiretroviral agents among HIV-infected adults and adolescents". Ann. Intern. Med. 137 (5 Pt 2): 381–433. PMID 12617573. {{cite journal}}: Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)
  2. ^ Barr SD, Smiley JR, Bushman FD (2008). "The interferon response inhibits HIV particle production by induction of TRIM22". PLoS Pathog. 4 (2): e1000007. doi:10.1371/journal.ppat.1000007. PMC 2279259. PMID 18389079. {{cite journal}}: Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link) CS1 maint: unflagged free DOI (link)
  3. ^ Panacos Pharmaceuticals. "Clinical Trial: Phase 2 Safety and Efficacy Study of Bevirimat Functional Monotherapy in HIV Treatment-Experienced Patients for 2 Weeks*". ClinicalTrials.gov. Retrieved 2007-08-28.
  4. ^ "The Health Benefits of Black Cumin". Retrieved 2010-10-15. {{cite web}}: Cite has empty unknown parameter: |coauthors= (help)
  5. ^ "A Study of AL721 in HIV-Infected Patients With Swollen Lymph Nodes - Full Text View - ClinicalTrials.gov". Retrieved 2010-10-15. {{cite web}}: Cite has empty unknown parameter: |coauthors= (help)
  6. ^ "Complete Chinese Cucumber information from Drugs.com". Retrieved 2010-10-15. {{cite web}}: Cite has empty unknown parameter: |coauthors= (help)
  7. ^ "Herbs, Supplements and HIV - The Body". Retrieved 2010-10-15. {{cite web}}: Cite has empty unknown parameter: |coauthors= (help)
  8. ^ eCAM 2005 2(3):285-299; doi:10.1093/ecam/neh107 http://ecam.oxfordjournals.org/cgi/content/full/2/3/285
  9. ^ Gordon M, Bihari B, Goosby E (1998). "A placebo-controlled trial of the immune modulator, lentinan, in HIV-positive patients: a phase I/II trial". Journal of Medicine. 29 (5–6): 305–30. PMID 10503166.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  10. ^ Tochikura TS, Nakashima H, Yamamoto N (1989). "Antiviral agents with activity against human retroviruses". Journal of Acquired Immune Deficiency Syndromes. 2 (5): 441–7. PMID 2477523.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  11. ^ Suzuki H, Okubo A, Yamazaki S, Suzuki K, Mitsuya H, Toda S (1989). "Inhibition of the infectivity and cytopathic effect of human immunodeficiency virus by water-soluble lignin in an extract of the culture medium of Lentinus edodes mycelia (LEM)". Biochemical and Biophysical Research Communications. 160 (1): 367–73. doi:10.1016/0006-291X(89)91665-3. PMID 2469420. {{cite journal}}: Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)
  12. ^ Wang HX, Ng TB (2000). "Isolation of a novel ubiquitin-like protein from Pleurotus ostreatus mushroom with anti-human immunodeficiency virus, translation-inhibitory, and ribonuclease activities". Biochemical and Biophysical Research Communications. 276 (2): 587–93. doi:10.1006/bbrc.2000.3540. PMID 11027517. {{cite journal}}: Unknown parameter |month= ignored (help)
  13. ^ Collins RA, Ng TB (1997). "Polysaccharopeptide from Coriolus versicolor has potential for use against human immunodeficiency virus type 1 infection". Life Sciences. 60 (25): PL383–7. doi:10.1016/S0024-3205(97)00294-4. PMID 9194694.
  14. ^ Odani S, Tominaga K, Kondou S (1999). "The inhibitory properties and primary structure of a novel serine proteinase inhibitor from the fruiting body of the basidiomycete, Lentinus edodes". European Journal of Biochemistry. 262 (3): 915–23. doi:10.1046/j.1432-1327.1999.00463.x. PMID 10411656. {{cite journal}}: Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)
  15. ^ Lori, F.; Foli, A.; Groff, A.; Lova, L.; Whitman, L.; Bakare, N.; Pollard, R. B.; Lisziewicz, J. Optimal suppression of HIV replication by low-dose hydroxyurea through the combination of antiviral and cytostatic ('virostatic') mechanisms. AIDS, 2005, 19, 1173-81
  16. ^ Perelson AS, Neumann AU, Markowitz M, Leonard JM, Ho DD (1996). "HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time". Science. 271 (5255): 1582–6. doi:10.1126/science.271.5255.1582. PMID 8599114.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  17. ^ . PMID 8896496. {{cite journal}}: Cite journal requires |journal= (help); Missing or empty |title= (help)
  18. ^ United States Department of Health and Human Services (2004). "A Guide to Primary Care for People With HIV/AIDS, 2004 Edition" (PDF). Retrieved 2006-07-03.
  19. ^ Attacking AIDS with a 'Cocktail' Therapy
  20. ^ AIDS Education Online (2005). "HIV Medication Education, copyright 2004" (Plain text). Retrieved 2008. {{cite web}}: Check date values in: |accessdate= (help)
  21. ^ Attention: This template ({{cite pmid}}) is deprecated. To cite the publication identified by PMID 7614897, please use {{cite journal}} with |pmid=7614897 instead.
  22. ^ Levine C, Dubler NN, Levine RJ (1991). "Building a new consensus: ethical principles and policies for clinical research on HIV/AIDS". IRB. 13 (1–2): 1–17. PMID 11659323. {{cite journal}}: |access-date= requires |url= (help); External link in |title= (help)CS1 maint: multiple names: authors list (link)
  23. ^ a b Blott KW (1991). "Administration of zidovudine for treatment of infection due to human immunodeficiency virus". Reviews of Infectious Diseases. 13 (1): 186–7. PMID 2017626.
  24. ^ Attention: This template ({{cite pmid}}) is deprecated. To cite the publication identified by PMID 7616996, please use {{cite journal}} with |pmid=7616996 instead.
  25. ^ Attention: This template ({{cite pmid}}) is deprecated. To cite the publication identified by PMID 10902643, please use {{cite journal}} with |pmid=10902643 instead.
  26. ^ Kitahata MM, Gange SJ, Abraham AG, Merriman B, Saag MS, Justice AC, Hogg RS, Deeks SG, Eron JJ, Brooks JT, Rourke SB, Gill MJ, Bosch RJ, Martin JN, Klein MB, Jacobson LP, Rodriguez B, Sterling TR, Kirk GD, Napravnik S, Rachlis AR, Calzavara LM, Horberg MA, Silverberg MJ, Gebo KA, Goedert JJ, Benson CA, Collier AC, Van Rompaey SE, Crane HM, McKaig RG, Lau B, Freeman AM, Moore RD (2009). "Effect of early versus deferred antiretroviral therapy for HIV on survival". N. Engl. J. Med. 360 (18): 1815–26. doi:10.1056/NEJMoa0807252. PMC 2854555. PMID 19339714. {{cite journal}}: Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)
  27. ^ Rachlis AR, Zarowny DP (1998). "Guidelines for antiretroviral therapy for HIV infection. Canadian HIV Trials Network Antiretroviral Working Group". CMAJ. 158 (4): 496–505. PMC 1228924. PMID 9627563. {{cite journal}}: Unknown parameter |month= ignored (help)
  28. ^ a b Panel on Antiretroviral Guidelines for Adults and Adolescents (2009-12-01). Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents (PDF). United States Department of Health and Human Services. p. i. Retrieved 2010-10-12.
  29. ^ World Health Organization (2003). "Scaling up retroviral therapy in resource limited settings" (PDF). Retrieved 2006-01-17.
  30. ^ UK Group of Transmitted HIV Drug Resistance (2005). "Time trends in primary resistance to HIV drugs in the United Kingdom: multicentre observational study". Brit Med J. 331 (7529): 1368–71. doi:10.1136/bmj.38665.534595.55. PMC 1309643. PMID 16299012.
  31. ^ Hammer, Eron, Reiss, et al. JAMA 2008; 300:555-570
  32. ^ Hirsch MS, Gunthard HF, Schapiro, et al. Clin Infect Dis 2008; 47: 266-285
  33. ^ a b Department of Health and Human Services (2009). "HIV and Its Treatment: What You Should Know" (PDF). Retrieved 2006-11-04. {{cite web}}: Unknown parameter |month= ignored (help)
  34. ^ Working Group on Antiretroviral Therapy and Medical Management of HIV-Infected Children (November 3, 2005). "Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection" (PDF). Department of Health and Human Services. Retrieved 2006-01-17.
  35. ^ Smith DK, Grohskopf LA, Black RJ; et al. (2005). "Antiretroviral postexposure prophylaxis after sexual, injection-drug use, or other nonoccupational exposure to HIV in the United States: recommendations from the U.S. Department of Health and Human Services". MMWR Recomm Rep. 54 (RR-2): 1–20. PMID 15660015. {{cite journal}}: Explicit use of et al. in: |author= (help); Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)
  36. ^ a b http://www.who.int/entity/hiv/pub/guidelines/PEP/en/index.html
  37. ^ http://www.who.int/entity/hiv/pub/guidelines/pmtctguidelines3.pdf
  38. ^ Coovadia H (2004). "Antiretroviral agents--how best to protect infants from HIV and save their mothers from AIDS". N. Engl. J. Med. 351 (3): 289–92. doi:10.1056/NEJMe048128. PMID 15247337. {{cite journal}}: Unknown parameter |month= ignored (help)
  39. ^ Saitoh A, Hull AD, Franklin P, Spector SA (2005). "Myelomeningocele in an infant with intrauterine exposure to efavirenz". J Perinatol. 25 (8): 555–6. doi:10.1038/sj.jp.7211343. PMID 16047034. {{cite journal}}: Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)
  40. ^ Beardsley T (1998). "Coping with HIV's ethical dilemmas". Scientific American. 279 (1): 106–7. PMID 9648307. {{cite journal}}: Unknown parameter |month= ignored (help)
  41. ^ Ian McNicholl (August 2004, July 2005). "Adverse Events of Antiretroviral Drugs". University of California San Francisco. Retrieved 2006-01-07. {{cite web}}: Check date values in: |date= (help)

Further reading

Retrieved from "https://en.wikipedia.org/w/index.php?title=Management_of_HIV/AIDS&oldid=391471560"